Fennec Pharmaceuticals Inc.
FENC
$11.29
-$0.06-0.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 75.70% | 64.98% | -6.09% | -21.39% | -31.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.83% | 64.98% | -6.09% | -21.39% | -31.88% |
| Cost of Revenue | 10.37% | 31.73% | 18.22% | -16.59% | 54.83% |
| Gross Profit | 85.42% | 68.56% | -7.84% | -21.73% | -35.92% |
| SG&A Expenses | 43.68% | 32.76% | 13.10% | -8.31% | -3.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.41% | 31.93% | 13.24% | -8.83% | -0.10% |
| Operating Income | 88.37% | 53.32% | -344.67% | -376.90% | -264.87% |
| Income Before Tax | 73.42% | 41.23% | -13,471.83% | -480.32% | -526.76% |
| Income Tax Expenses | -59.45% | -70.96% | -70.96% | -- | -- |
| Earnings from Continuing Operations | 72.99% | 41.99% | -2,134.40% | -512.53% | -540.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.99% | 41.99% | -2,134.40% | -512.53% | -540.11% |
| EBIT | 88.37% | 53.32% | -344.67% | -376.90% | -264.87% |
| EBITDA | 89.33% | 53.78% | -283.55% | -206.67% | -201.29% |
| EPS Basic | 74.08% | 46.06% | -3,067.62% | -557.85% | -533.14% |
| Normalized Basic EPS | 89.61% | 57.74% | -4,688.89% | -521.10% | -514.78% |
| EPS Diluted | 73.03% | 46.99% | -293.61% | -151.55% | -1,328.57% |
| Normalized Diluted EPS | 88.82% | 57.68% | -366.67% | -134.77% | -1,172.36% |
| Average Basic Shares Outstanding | 16.24% | 10.35% | 4.70% | 1.88% | 2.14% |
| Average Diluted Shares Outstanding | 19.05% | 11.46% | 0.92% | -1.82% | -1.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |